Brigatinib in Crizotinib-Refractory ALK plus NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial

被引：11

作者：

Camidge, D. Ross ^{[1
]}

Tiseo, Marcello ^{[2
]}

Ahn, Myung-Ju ^{[3
]}

Reckamp, Karen ^{[4
]}

Hansen, Karin ^{[5
]}

Kim, Sang-We ^{[6
]}

Huber, Rudolf ^{[7
]}

West, Howard ^{[8
]}

Groen, Harry ^{[9
]}

Hochmair, Maximilian ^{[10
]}

Leighl, Natasha ^{[11
]}

Gettinger, Scott ^{[12
]}

Langer, Corey ^{[13
]}

Paz-Ares, Luis ^{[14
]}

Smit, Egbert ^{[15
]}

Kim, Edward ^{[16
]}

Reichmann, William ^{[17
]}

Clackson, Tim ^{[17
]}

Kerstein, David ^{[17
]}

Haluska, Frank ^{[17
]}

Kim, Dong-Wan ^{[18
]}

机构：

[1] Univ Colorado, Ctr Canc, Aurora, CO USA

[2] Univ Hosp Parma, Med Oncol, Parma, Italy

[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Meidicine, Seoul, South Korea

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Odense Univ Hosp, Odense, Denmark

[6] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[7] Univ Hosp Munich, Munich, Germany

[8] Swedish Canc Inst, Med Oncol, Seattle, WA USA

[9] Univ Med Ctr Groningen, Groningen, Netherlands

[10] Otto Wagner Hosp, Dept Resp & Crit Care Med, Vienna, Austria

[11] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[12] Yale Canc Ctr, New Haven, CT USA

[13] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[14] Hosp Univ Doce Octubre, Madrid, Spain

[15] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[16] Carolinas Healthcare Syst, Levine Canc Inst, Solid Tumor Oncol, Charlotte, NC USA

[17] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA

[18] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期

关键词：

ALK; brigatinib; NSCLC; TKI;

D O I：

10.1016/j.jtho.2016.11.1643

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.02a-013

引用

页码：S1167 / S1169

页数：3

共 50 条

[21] Brigatinib (BRG) in ALK plus crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.
Gettinger, Scott N.
Huber, Rudolf M.
Kim, Dong-Wan
Bazhenova, Lyudmila
Hansen, Karin Holmskov
Tiseo, Marcello
Langer, Corey J.
Paz-Ares, Luis G.
West, Howard
Reckamp, Karen L.
Weiss, Glen J.
Smit, Egbert F.
Hochmair, Maximilian
Kim, Sang-We
Ahn, Myung-Ju
Kim, Edward S.
Groen, Harry J. M.
Pye, Joanna
Vranceanu, Florin
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[22] Updated Results from the Phase 3 ALTA-1L Trial of Brigatinib (BRG) vs. Crizotinib (CRZ) in ALK Inhibitor-Naive Advanced ALK plus NSCLC
Griesinger, Frank
Camidge, D. Ross
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James Chih-Hsin
Han, Ji Youn
Hochmair, Maximilian
Lee, Hyeong
Delmonte, Angelo
Garcia Compelo, Maria Rosario
Kim, Dong-Wan
Felip, Enriqueta
Califano, Raffaele
Spire, Alexander
Gettinger, Scott N.
Tiseo, Marcello
Lin, Huamao M.
Ni, Quanhong
Zhang, Pingkuan
Popat, Sanjay
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 232 - 232
[23] Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI-naive ALK plus NSCLC: Final results from ALTA-1L
Popat, S.
Kim, H. R.
Ahn, M-J.
Yang, J. C.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S. N.
Tiseo, M.
Lin, H. M.
Liu, Y.
Vranceanu, F.
Camidge, D. R.
ANNALS OF ONCOLOGY, 2021, 32 : S954 - S955
[24] Brigatinib (BRG) vs Crizotinib (CRZ) in Patients (Pts) With ALK Inhibitor-Naive Advanced ALK plus NSCLC from ALTA-1L
Yang, James C. H.
Kim, Hye R.
Ahn, Myung-Ju
Han, Ji-Youn
Hochmair, Maximilian J.
Lee, Ki H.
Delmonte, Angelo
Garcia Campelo, Maria R.
Kim, Dong-Wan
Felip, Enriqueta
Califano, Raffaele
Spira, Alexander
Gettinger, Scott
Tiseo, Marcello
Haney, Jeff
Kerstein, David
Popat, Sanjay
Camidge, D. R.
ANNALS OF ONCOLOGY, 2019, 30
[25] Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
Yang, James Chih-Hsin
Liu, Geoffrey
Lu, Shun
He, Jianxing
Burotto, Mauricio
Ahn, Myung-Ju
Kim, Dong-Wan
Liu, Xiaoqing
Zhao, Yanqiu
Vincent, Sylvie
Yin, Jiani
Ma, Xin
Lin, Huamao M.
Popat, Sanjay
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (12) : 1743 - 1755
[26] Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK1 NSCLC: Updated results from the phase III ALTA-1L trial
Camidge, R.
Kim, H. R.
Ahn, M-J.
Yang, J. C-H.
Han, J-Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Garcia Campelo, M. R.
Kim, D-W.
Griesinger, F.
Felip, E.
Califano, R.
Spira, A.
Gettinger, S.
Tiseo, M.
Ni, Q.
Zhang, P.
Popat, S.
ANNALS OF ONCOLOGY, 2019, 30
[27] Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Camidge, D. Ross
Kim, Hye Ryun
Ahn, Myung-Ju
Yang, James C. H.
Han, Ji-Youn
Hochmair, Maximilian J.
Lee, Ki Hyeong
Delmonte, Angelo
Campelo, Maria Rosario Garcia
Kim, Dong-Wan
Griesinger, Frank
Felip, Enriqueta
Califano, Raffaele
Spira, Alexander I.
Gettinger, Scott N.
Tiseo, Marcello
Lin, Huamao M.
Liu, Yuyin
Vranceanu, Florin
Niu, Huifeng
Zhang, Pingkuan
Popat, Sanjay
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) : 2091 - 2108
[28] Depth of Target Lesion Response to Brigatinib and Its Association With Outcomes in Patients With ALK plus NSCLC in the ALTA Trial
Camidge, D. R.
Tiseo, M.
Ahn, M.
Reckamp, K.
Hansen, K.
Kim, S.
Huber, R.
West, H.
Groen, H.
Hochmair, M.
Leighl, N.
Gettinger, S.
Langer, C.
Paz-Ares, L.
Smit, E.
Kim, E.
Reichmann, W.
Kerstein, D.
Kim, D.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1892 - S1892
[29] Brigatinib (BRG) in patients (pts) with ALK plus non-small cell lung cancer (NSCLC): Updates from a phase 1/2 trial.
Bazhenova, Lyudmila
Gettinger, Scott N.
Langer, Corey J.
Salgia, Ravi
Gold, Kathryn A.
Rosell, Rafael
Shaw, Alice Tsang
Weiss, Glen J.
Haney, Jeff
Rivera, Victor M.
Kerstein, David
Camidge, D. Ross
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[30] Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results
Gettinger, Scott N.
Bazhenova, Lyudmila
Salgia, Ravi
Langer, Corey J.
Gold, Kathryn A.
Rosell, Rafael
Shaw, Alice
Weiss, Glen J.
Dorer, David J.
Rivera, Victor M.
Conlan, Maureen G.
Kerstein, David
Camidge, Ross
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S238 - S239

← 1 2 3 4 5 →